Trial
NCT02156674
Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
BioMarin Pharmaceutical
Condition
Maroteaux-Lamy Syndrome
Intervention
Naglazyme®
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-23